Dr. Martens plc (LON:DOCS - Get Free Report)'s stock price rose 25.8% during mid-day trading on Thursday . The stock traded as high as GBX 76 ($1.03) and last traded at GBX 75.40 ($1.02). Approximately 8,364,149 shares changed hands during trading, an increase of 271% from the average daily volume of 2,253,765 shares. The stock had previously closed at GBX 59.95 ($0.81).
Wall Street Analysts Forecast Growth
Separately, Royal Bank of Canada cut their target price on Dr. Martens from GBX 7,000 ($95.06) to GBX 6,000 ($81.48) and set a "sector perform" rating on the stock in a report on Monday, May 19th.
Read Our Latest Stock Report on Dr. Martens
Dr. Martens Price Performance
The firm has a market capitalization of £731.96 million, a P/E ratio of 10.69, a PEG ratio of 6.40 and a beta of 0.11. The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13. The company has a fifty day moving average of GBX 54.24 and a 200 day moving average of GBX 62.52.
Dr. Martens (LON:DOCS - Get Free Report) last announced its earnings results on Thursday, June 5th. The company reported GBX 2.40 ($0.03) earnings per share for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. Sell-side analysts predict that Dr. Martens plc will post 2.5809394 earnings per share for the current year.
Dr. Martens Cuts Dividend
The firm also recently disclosed a dividend, which was paid on Tuesday, April 8th. Stockholders of record on Thursday, March 6th were given a GBX 0.85 ($0.01) dividend. This represents a dividend yield of 1.47%. The ex-dividend date was Thursday, March 6th. Dr. Martens's dividend payout ratio (DPR) is presently 42.53%.
Insider Activity
In other Dr. Martens news, insider Giles Wilson bought 32,640 shares of the stock in a transaction on Tuesday, March 25th. The stock was acquired at an average cost of GBX 54 ($0.73) per share, for a total transaction of £17,625.60 ($23,934.82). Insiders have acquired 33,206 shares of company stock valued at $1,792,771 in the last ninety days. 4.36% of the stock is owned by company insiders.
Dr. Martens Company Profile
(
Get Free Report)
Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking
for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical
movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage
and, six decades later, “Docs” or “DMs” are worn by people around the world who use them as a symbol of
empowerment and their own individual attitude.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dr. Martens, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Martens wasn't on the list.
While Dr. Martens currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
